Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020

Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.

[thumbnail of Oncology Fact Sheet Nr.7_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
77kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 400-560 Intestines WI Digestive system > WI 600-650 Anus. Rectum
Language:	English
Series Name:	Oncology Fact Sheet Nr. 7
Deposited on:	02 Jun 2020 15:51
Last Modified:	31 Jul 2020 09:46

Repository Staff Only: item control page